Effectiveness of Convalescent Immune Plasma Therapy

Bagcilar Training and Research Hospital

Status: Completed

Conditions: Acute Respiratory Distress Syndrome

Treatments: Other: Convalescent Immune Plasma

Study type: Interventional

Funder types: Other

Identifiers

NCT04442958

2020.05.2.14.070

Details and patient eligibility

About

The aim of the study is to evaluate the safety, improvement of clinical symptoms and laboratory parameters of convalescent immune plasma treatment in severe Covid-19 patients with ARDS.

Full description

The aim of the study is to evaluate the safety, improvement of clinical symptoms with hypoxemia, metabolic and laboratory parameters of patients with convalescent immune plasma treatment in severe Covid-19 patients followed up in critical care unit.

Enrollment: 60 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria Clinical diagnosis of Covid-19

Exclusion Criteria Age lower than 18 Lower plasma IgA levels PaO2/FiO2 higher than 300 mmHg SpO2 higher than 90

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

60 participants in 2 patient groups

Convalescent Plasma Therapy Group

Experimental group

Description:

One dose of 200 mL of convalescent ımmune plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to standart critical care treatment.

Treatment:

Other: Convalescent Immune Plasma

Non-Plasma Therapy Group

No Intervention group

Description:

Standart critical care treatment group